Stemline Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. In December 2018, the FDA approved the Company's first product, ELZONRIS (formerly SL-401), a CD123-directed cytotoxin, for the treatment of adult and pediatric patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). ELZONRIS remains the first and only FDA approved drug indicated for BPDCN and the first and only FDA approved CD123-targeted therapy. In January 2019, Stemline submitted a marketing authorization application (MAA) to the EMA for ELZONRIS. ELZONRIS is also being evaluated in clinical trials in additional indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF) and others